Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). This is a disease with significant commercial opportunity as improved therapies are needed.
Following termination of development in a pivotal Phase 2B/3 levodopa-induced dyskinesia associated with Parkinson's disease (PD-LID) study due to slow recruitment of patients and the consequential excessive costs of continuing development (announced June 17, 2022), we have initiated discussions with potential strategic partners to reinitiate Phase 2 development of dipraglurant in PD-LID or an alternative indication, including post-stroke recovery, substance use disorders (SUD) and pain.
We believe that, subject to regulatory approval, dipraglurant may offer an innovative and differentiated treatment approach from existing therapies in a number of disease areas where there is a significant need for improved treatment options.
We have received orphan drug designation from the FDA, for dipraglurant in PD-LID.